Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.775 (4.11%)
Spread: 1.25 (6.793%)
Open: 19.65
High: 19.65
Low: 19.65
Prev. Close: 18.875
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

6 Jun 2013 07:00

RNS Number : 4128G
BATM Advanced Communications Ld
06 June 2013
 



6 June 2013

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update

 

BATM Advanced Communications Limited (LSE: BVC; TASE: BATM), a leading provider of real-time technologies for the networked telecoms and medical laboratory equipment markets, provides the following update on trading.

 

As stated in the Group's interim management statement for the first quarter of 2013, BATM was on schedule to deliver solid growth in 2013. At the beginning of Q2 2013, the Group was gearing up its production in the Medical division businesses of diagnostics and pathogenic waste management in response to significant demand for its products. In order to meet this demand in the diagnostics business, BATM also increased spending on seeking registration. Disappointingly, components supplied by third parties failed to arrive during May as scheduled, and consequently BATM was unable to fulfill orders and was forced to postpone deliveries. However, the backlog remains substantial and, with certain components required to complete some orders having been received, the Group is working towards clearing this in the second half of 2013.

 

Separately, due to ongoing global economic and commercial uncertainty, the Group has re-enforced its policy of tight credit control for certain customers of the distribution business of the Medical division whereby shipping should only occur once payment has been received by BATM or it has complete confidence that payment will be forthcoming. Consequently, and in accordance with this policy, the Group was forced to stop supplies to certain major customers globally during May 2013. This has resulted in revenues in this business being lower than anticipated.

 

The consequence of the above factors is that the Group expects first half 2013 revenue and profit to be materially below management's expectations. In contrast, the Group has opened trading in June 2013 very well and its businesses are returning to normality. Accordingly, the Group expects H2 2013 performance to be in line with management's expectations. For the full year to 31 December 2013 as a whole, the Group still expects to achieve higher revenue and profit than for the full year to 31 December 2012.

 

Looking ahead, the fundamentals of the business remain strong. BATM's Telecom division's T-Metro 8000 platform and Edge Genie service management solution continue to attract interest from customers globally. The Group has also been asked to join consortia bidding for large, long-term contracts, and the Board is confident of being awarded contracts in thenear future. In the Medical division, the diagnostics business continues to grow and has a strong order book and backlog. In addition, the Group continues to increase the installations of its Integrated Sterilizer and Shredder systems in the sterilization business.

 

CELARE, the Group's subsidiary focusing on networks security, continues to perform well in its contract with the Israeli Defence Force. Due to the growing demand for products and services to protect networks against cyber-attacks, BATM has been in discussions with the relevant authorities to allow it to market part of its product line globally. BATM anticipates successful conclusion to these talks in 2013 and has accelerated its strategic plan for this business.

 

BATM will provide further details on trading for the first half of the year in its interim results announcement in August 2013.

Enquiries 

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Ofer Bar-Ner, Chief Financial Officer

finnCap

Stuart Andrews, Henrik Persson - Corporate Finance

+44 20 7220 0500

Brian Patient, Stephen Norcross - Corporate Broking

Shore Capital

Pascal Keane

+44 20 7408 4090 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVELFBXQFFBBD
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.